Skip to content
Sign in
In depthStableHealthFirst published 2026-11-20 08:00

Isomorphic Labs partners with MSD to apply AI-driven drug design to oncology, with upfront payment and milestone royalties

The collaboration, announced on 19 November 2026, joins Isomorphic Labs' in‑silico platform with MSD's curated data sets. It aims to generate small‑molecule candidates for a strategically important cancer indication while assigning development and commercialization to MSD.

Nov. 19, 2026

Isomorphic Labs and MSD announced their research collaboration on Nov. 19, 2026.1

$5 billion

In November 2026, Isomorphic Labs announced a Series C financing led by Greenoaks and Sequoia Capital.4

End of 2026

Isomorphic Labs’ stated goal is to move its first treatment programs into clinical trials by the end of 2026, after an earlier end-of-2025 goal.3

Story

Isomorphic Labs partners with MSD to apply AI-driven drug design to oncology, with upfront payment and milestone royalties

1 1 1 1 1

1 1 1 1 1 1

1 1 1 1 1 1

1 2 2 1 12 12

4 4 4 4 4 234

1 1 3 1 13 13

3 3 3 1 3 3

1 1 1 1 1 13

1 1 234 1 1 34

Structure

Who is connected to whom
  1. 1Isomorphic Labs
  2. uses →Fact
  3. located in →Fact
    3LondonGeography
  4. ← invests inFact
    4AlphabetCompany
  5. enables →Fact
    5bioresilienceIndustry
  6. produces →Fact
    6IsoDDEProduct

History

How it came to this
  1. January 2024Earlier pharmaceutical partnershipsIsomorphic Labs announced partnerships with Eli Lilly and Novartis.
  2. May 2026Series B financing announcedThe company announced a $2.1 billion Series B.
  3. November 2026Series C financing announcedIsomorphic Labs announced a $5 billion Series C led by Greenoaks and Sequoia Capital.
  4. Nov. 19, 2026MSD collaboration announcedThe companies announced a research collaboration to seek small-molecule therapeutic candidates for an oncology indication.
  5. NowAnnounced Isomorphic Labs–MSD oncology drug-discovery collaboration announced

Impact

Spreading outward, level by level
  1. Level 1Discovery work

    Isomorphic Labs will provide in-silico predictions and molecular designs using its IsoDDE engine, while MSD will provide proprietary, curated datasets. The intended output is oncology candidates at the discovery stage, not clinical products.1

    Fact
  2. Level 2Development and product responsibilities

    MSD will lead preclinical and clinical development, manufacturing, and commercialization for products arising from the collaboration.1

    Fact
  3. Level 3Isomorphic Labs’ potential compensation

    The terms include an upfront payment, potential milestone payments and tiered net-sales royalties; Isomorphic Labs may choose to co-fund development for higher royalties.1

    Fact
  4. Level 4Potential progress toward patient testing

    Any candidates would still need testing to establish safety and effectiveness in people, and clinical development carries substantial risk of failure. The collaboration’s success would therefore depend on candidates progressing beyond discovery.13

    Fact

Sources

What each source supports
1
PR Newswire news releases
2026-11-19 19:27
Original ↗
Supports 14 points
Citing: Isomorphic Labs, MSD, Sarah Skerratt, George Addona, MSD Research Laboratories, Demis Hassabis, World Economic Forum
2
钛媒体
2026-11-18 09:51
Original ↗
Supports 1 points
Citing: Isomorphic Labs
3
cnBeta
2026-11-18 05:29
Original ↗
Supports 3 points
Citing: Demis Hassabis, World Economic Forum, Isomorphic Labs
4
BioPharma Dive
2026-11-17 15:51
Original ↗
Supports 2 points
Citing: Isomorphic Labs

Written by AI from the sources listed below: every fact was checked word for word against its source, and inference is marked apart. How we write

2026-11-19 23:13 First published